Online inquiry

IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8606MR)

This product GTTS-WQ8606MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8606MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14018MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ6283MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ9008MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ7966MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ6815MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ3258MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ5138MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ9769MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW